Beijing Konruns Pharmaceutical Co 603590.SS · CNY

Its shares trade on Shanghai under the ticker 603590.SS. It has been listed since 27 August 2018. In the fiscal year to 31 December 2025, it reported revenue of CN¥915.1m and net income of CN¥166.0m. At that date it held total assets of CN¥4.09bn and shareholders' equity of CN¥3.21bn.

Beijing Konruns Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of new drugs, with a focus on new special drugs. The company is headquartered in Beijing, Beijing. The company went IPO on 2018-08-27. The firm's main product Suling belongs to the haemocoagulase drug that activates the coagulation process, which is mainly used for hemostasis of superficial wound bleeding in surgical operations as well as the bleeding caused by postoperative, trauma and disease. The Company’s present products under research include a range of innovative and generic drugs for tumors and blood. The firm mainly distributes its products in the domestic market.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Jianhua LiuChairman of the Board, since 2006
• Mr. Zhanqi NiuPresident, Director, since 2023
• Mr. Xiaohan LiuActing Chief Financial Officer, Director, since 2011
• Mr. Xiaodong HuangSecretary of the Board
• Mr. Yongxin HanDirector
• Mr. Jin LiDirector
• Ms. Xijuan WangDirector, since 2013
• Mr. Lijia FuIndependent Director
• Mr. Junyan LiuIndependent Director
• Mr. Yonggong ZhaiIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.